MSD

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Wednesday, September 22, 2021 - 11:30am

In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.

Key Points: 
  • In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.
  • Matthias Dobbelstein, M.D., Professor of Molecular Oncology, University Medical Center Goettingen, added, "We are proud of the results of our preclinical work.
  • We were very pleased with this license agreement with Immunic and look forward to future results with these very promising combinations."
  • Although the technology in-licensed by Immunic includes the potential combination of DHODH inhibitors with nucleoside analogues, including molnupiravir, Immunic does not have any rights to molnupiravir itself.

DGAP-News: Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19

Wednesday, September 22, 2021 - 11:59am

Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19- Preclinical Combination Data Suggests Extra-Ordinary Synergy Between Certain DHODH Inhibitors and Nucleoside Analogues -- Combination of IMU-838 and N4-Hydroxycytidine Reduced SARS-CoV-2 Virus Levels, Including the Delta Variant, Down to the Detection Limit -NEW YORK and GOETTINGEN, Germany, September 22, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced the execution of an in-license agreement with the University Medical Center Goettingen, Germany, covering the combination of DHODH inhibitors and nucleoside analogues to treat viral infections (COVID-19 and Influenza). Terms of the agreement were not disclosed.
Preclinical research recently completed by the parties and their collaborators[1] has shown that certain DHODH inhibitors, including Immunic's lead asset, IMU-838, strongly synergize with selected nucleoside analogues to inhibit SARS-CoV-2 replication in vitro. For instance, in an in vitro test system, IMU-838 alone showed an up to 99.9% reduction in viral RNA at concentrations of 5 μM, which is well within the exposure levels seen in prior clinical trials. Likewise, N4-hydroxycytidine (NHC), the active metabolite of molnupiravir[2], alone, was associated with an up to 99% reduction in viral RNA at concentrations of 100 nM. Compared to single agent activity, the combination of IMU-838 and NHC achieved an extra-ordinary reduction in viral RNA, down to the limit of detection, reducing SARS-CoV-2 RNA by up to seven log units (corresponding to 0.00001% viral RNA remaining). This powerful reduction of virus replication in vitro was demonstrated across multiple SARS-CoV-2 variants, including alpha, beta and delta, highlighting the independence of this approach to mutant virus forms. In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro. The company plans to present detailed data at an upcoming scientific conference.
"Research by the University Medical Center Goettingen and other research partners revealed a profound degree of synergy in vitro when combining certain nucleoside analogues with DHODH inhibitors, including both our lead asset IMU-838 and other of our preclinical molecules," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic. "Recalling IMU-838's clinical activity against COVID-19 in our phase 2 CALVID-1 trial published earlier this year, and in light of recent exacerbations in COVID-19, worldwide, we are very excited to have in-licensed this technology to incorporate into our pandemic preparedness effort. However, with the extra-ordinary wealth of activity already ongoing at the company in other programs, we intend to evaluate and pursue the best possible strategic option for this program, including potential partnership, collaboration or external funding."

Key Points: 
  • Immunic and the University Medical Center Goettingen Sign License Agreement Covering the Combination of DHODH Inhibitors and Nucleoside Analogues to Treat Viral Infections, Including COVID-19
    The issuer is solely responsible for the content of this announcement.
  • In addition to molnupiravir, Immunic is exploring alternate nucleoside analogues, some of which have shown very promising antiviral activity in vitro.
  • Matthias Dobbelstein, M.D., Professor of Molecular Oncology, University Medical Center Goettingen, added, "We are proud of the results of our preclinical work.
  • Although the technology in-licensed by Immunic includes the potential combination of DHODH inhibitors with nucleoside analogues, including molnupiravir, Immunic does not have any rights to molnupiravir itself.

St. Louis' Enormous Deer Creek Wastewater Tunnel Completed with Penetron Treatment

Tuesday, September 21, 2021 - 9:00am

The Deer Creek Tunnel is a key element of the Metropolitan St. Louis Sewer District's (MSD) "Project Clear" initiative to eliminate sewer overflows during heavy storms due to the limits of older wastewater collection and treatment systems.

Key Points: 
  • The Deer Creek Tunnel is a key element of the Metropolitan St. Louis Sewer District's (MSD) "Project Clear" initiative to eliminate sewer overflows during heavy storms due to the limits of older wastewater collection and treatment systems.
  • While the concrete lining of the 4.3-mile-long tunnel of the Deer Creek Sanitary Tunnel project has been completed, plenty of work remains before the tunnel is officially commissioned and begins operation in late 2022.
  • The project contractor needed a solution to prevent microbially-induced corrosion (MIC) in the concrete lining of the Deer Creek Tunnel.
  • Penetron's antimicrobial admixture was used to treat over 17,050 yds3 of concrete used to line the Deer Creek Tunnel.

Organon Aims to Ignite Worldwide Conversation Around Unplanned Pregnancy

Tuesday, September 21, 2021 - 5:01am

Organon (NYSE: OGN), a global womens health company, is launching a Public Service Announcement (PSA) that aims to raise awareness and ignite a worldwide conversation about the staggering rates of unplanned pregnancy around the world.

Key Points: 
  • Organon (NYSE: OGN), a global womens health company, is launching a Public Service Announcement (PSA) that aims to raise awareness and ignite a worldwide conversation about the staggering rates of unplanned pregnancy around the world.
  • While we have seen a lot of progress in the area of reproductive health, the rates of unplanned pregnancy around the world continue to be high, said Dr. Sandy Milligan, M.D., J.D., head of Organon research and development.
  • There is no better time than ahead of World Contraception Day to focus on empowering women through education, information, empathy and conversation to help reduce unplanned pregnancy.
  • Organon invites women, their families, healthcare professionals and policy makers to visit https://hereforherhealth.com/unplanned/ to share their perspectives on how to help reduce the rates of unplanned pregnancy and join us on a collective mission of having the conversation.

MerckManuals.com Offers Key Takeaways on What We Have Learned about Telemedicine from the Pandemic

Monday, September 20, 2021 - 1:45pm

A recurring point made in the expanded essay is that with all healthcare visits, preparation is critical to making them productive.

Key Points: 
  • A recurring point made in the expanded essay is that with all healthcare visits, preparation is critical to making them productive.
  • "The rise of telehealth has transformed the healthcare arena," said Michael R. Wasserman, M.D., Merck Manuals editorial board member and contributor of the new content related to telemedicine.
  • "While there may be no substitute for an in-person office visit with a clinician, telemedicine clearly serves as a beneficial supplement to traditional patient care."
  • Takeaways about what the pandemic has taught us about telemedicine follow.

DGAP-News: Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus

Monday, September 20, 2021 - 12:13pm

Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus

Key Points: 
  • Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus
    The issuer is solely responsible for the content of this announcement.
  • Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus
    Laupheim, Germany and Milford, MA, USA, September 20, 2021 - Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, announced the appointment of Dr. Christian Schetter, Ph.D. as Chief Scientific Officer (CSO) of Rentschler Biopharma SE, where he will be responsible for process technology and innovation, effective 15 September 2021.
  • Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma, said: "I am delighted that Dr. Schetter has joined Rentschler Biopharma as our new Chief Scientific Officer.
  • Dr. Christian Schetter, Rentschler Biopharma's new CSO, added: "Rentschler Biopharma is known to deliver very high quality based on solid science.

Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific Officer, strengthening scientific focus

Monday, September 20, 2021 - 12:00pm

Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma, said: I am delighted that Dr. Schetter has joined Rentschler Biopharma as our new Chief Scientific Officer.

Key Points: 
  • Prof. Dr. Nikolaus F. Rentschler, Chairman of the Supervisory Board of Rentschler Biopharma, said: I am delighted that Dr. Schetter has joined Rentschler Biopharma as our new Chief Scientific Officer.
  • It is with great pleasure that I welcome him as our new CSO, commented Dr. Frank Mathias, CEO of Rentschler Biopharma.
  • Dr. Christian Schetter, Rentschler Biopharma's new CSO, added: Rentschler Biopharma is known to deliver very high quality based on solid science.
  • In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd.

AlbaCore Capital Group Continues to Expand with Three Senior Hires

Monday, September 20, 2021 - 10:14am

European credit specialist AlbaCore Capital Group (AlbaCore), today announces three senior hires to reinforce its Operations, Business Development and Investor Relations teams.

Key Points: 
  • European credit specialist AlbaCore Capital Group (AlbaCore), today announces three senior hires to reinforce its Operations, Business Development and Investor Relations teams.
  • As part of the growth of the AlbaCore platform, investing across the European credit spectrum with $8.5bn1 AUM, AlbaCore has bolstered its senior executive group.
  • Matthew Courey, Founding Partner and Chief Operating Officer at AlbaCore Capital Group, commented: We are excited to have Jenny, Tara and Micaela join the AlbaCore team.
  • AlbaCore Capital Group is one of Europes leading specialist credit investors focusing on public and private corporate credit markets.

DGAP-News: AiCuris starts pilot trial with proprietary immunomodulator AIC649, a unique therapy to prevent severe symptoms in SARS-CoV-2 infections

Monday, September 20, 2021 - 9:03am

AiCuris starts pilot trial with proprietary immunomodulator AIC649, a unique therapy to prevent severe symptoms in SARS-CoV-2 infections

Key Points: 
  • AiCuris starts pilot trial with proprietary immunomodulator AIC649, a unique therapy to prevent severe symptoms in SARS-CoV-2 infections
    The issuer is solely responsible for the content of this announcement.
  • AIC649 is an inactivated parapoxvirus (iPPVO), which was previously in development for the treatment of chronic HBV infections at AiCuris.
  • With this novel therapy we aim to protect patients with SARS-CoV-2 infections to develop a more severe form of COVID-19 including respiratory failure.
  • In addition, based on promising pre-clinical findings, AIC649 could have potential as therapy against other respiratory viral infections with pandemic potential."

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer

Saturday, September 18, 2021 - 2:05pm

These results highlight the critical role KEYTRUDA can play in improving outcomes for certain women with persistent, recurrent or metastatic cervical cancer.

Key Points: 
  • These results highlight the critical role KEYTRUDA can play in improving outcomes for certain women with persistent, recurrent or metastatic cervical cancer.
  • Cervical cancer is the fourth most commonly diagnosed cancer in women and the fourth leading cause of cancer-related death in women globally.
  • Selected KEYTRUDA (pembrolizumab) Indications in the U.S.
    KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.
  • KEYTRUDA, as a single agent, is indicated for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.